31 reports

  • CAUSES OF GASTRIC CANCER
  • Gastric cancer drugs market in EMEA

Market outlook of the global gastric cancer drugs market Technavio’s market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market’s healthy growth during the forecast period....

  • Gastric Cancer
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi S.A.
  • Gastric Cancer, Stage Grouping
  • Pipeline for Gastric Cancer, Global, 2016

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it...

  • Gastric Cancer
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group

Global Gastric Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Gastric Cancer
  • France
  • United States
  • World
  • Forecast

Gastric cancer

4546 5000 3864
  • FORECAST: GASTRIC CANCER
  • TREATMENT: GASTRIC CANCER

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies...

  • Gastric Cancer
  • East Asia
  • Japan
  • United States
  • Eli Lilly & Co.
  • Risk Factors and Comorbidities for Gastric Cancer
  • 8MM, Diagnosed Incident Cases of Gastric Cancer,

EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024 Summary Gastric cancer, also called stomach cancer, is a multifactorial disease that starts in the tissues lining the stomach. Gastric cancer usually begins in cells in the inner layer of the stomach and tends to develop slowly into the outer layer over many...

  • Gastric Cancer
  • China
  • Japan
  • World
  • Forecast

Europe Gastric Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Gastric Cancer
  • Europe
  • France
  • Germany
  • Forecast

Gastric Cancer -Epidemiology Forecast to 2027 ##.

  • Gastric Cancer
  • France
  • Germany
  • Italy
  • Spain

Gastric Cancer Drugs - R& D, Trends and Market Forecasts 2016-2026 ##.

  • Cancer
  • Gastric Cancer
  • Therapy
  • World
  • Market Size

Gastric Cancer Forecast and Market Analysis to 2024 FORECAST: GASTRIC CANCER (Published on ## December 2017) EXECUTIVE SUMMARY RECENT FORECAST UPDATES MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHODOLOGY BIBLIOG

  • Cancer
  • Gastric Cancer
  • European Union
  • Japan
  • United States

Gastric Cancer - Market Insight, Epidemiology and Market Forecast - 2027 ##.

  • Cancer
  • Gastric Cancer
  • Pathology
  • United States
  • Market Shares

Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets CHAPTER ## INTRODUCTION ## STUDY GOALS AND OBJECTIVES ## REASONS FOR DOING THE STUDY ## SCOPE AND FORMAT ## INTENDED AUDIENCE ## METHODOLOGY ## RELATED BCC RESEARCH REPORTS ## ANALYST' S CREDENTI

  • Cancer
  • Gastric Cancer
  • Pathology
  • Therapy
  • World
  • SYMPTOMS OF GASTRIC CANCER
  • CLINICAL GUIDELINES FOR GASTRIC CANCER

PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024 Summary Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common...

  • Gastric Cancer
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Drug analysis: Napabucasin Product Profiles BBI## : Gastric cancer napabucasin : Colorectal cancer (CRC) napabucasin : Non-small cell lung cancer (NSCLC) LIST OF FIGURES Figure ##: BBI## for gastric cancer – SWOT analysis Figure ##: Dat

  • Colorectal Cancer
  • Gastric Cancer
  • European Union
  • Japan
  • United States
  • STAGE DEFINITIONS FOR GASTRIC CANCER
  • SYMPTOMS OF GASTRIC CANCER

Gastric and Gastroesophageal Junction Adenocarcinoma - Japan Drug Forecast and Market Analysis to 2024 Summary Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer...

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • SYMPTOMS OF GASTRIC CANCER
  • CLINICAL GUIDELINES FOR GASTRIC CANCER

Gastric and Gastroesophageal Junction Adenocarcinoma - China Drug Forecast and Market Analysis to 2024 Summary Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer...

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • STAGE DEFINITIONS FOR GASTRIC CANCER
  • NIMOTUZUMAB'S DEVELOPMENT IN GASTRIC CANCER

Gastric and Gastroesophageal Junction Adenocarcinoma - US Drug Forecast and Market Analysis to 2024 Summary Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer...

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • STAGE DEFINITIONS FOR GASTRIC CANCER
  • NIMOTUZUMAB'S DEVELOPMENT IN GASTRIC CANCER

Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024 Summary Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer...

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Natalie Sacks to its Board of Directors ## Jul ##, 2017: Athenex, Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase ##b Clinical Trial in Gastric Cancer ## Jul ##, 2017: Five Prime Therapeutics Initiates Patient Dosing in Phase ## Clinical Safety

  • Clinical Trial
  • Gastric Cancer
  • Pharmaceutical
  • Therapy
  • World
  • DIFFERENT TYPES OF GASTRIC CANCER
  • 5.2 GLOBAL GASTRIC CANCER MARKET

Cancer is a condition where an error or mutation in the cell’s DNA occurs, causing it to grow at a rapid rate. A cancer cell continues living while a normal cell would die, thus, accumulating to form a tumor that can break off and spread throughout the body. Gastric cancer is when such a condition occurs in the stomach and has the tendency...

  • Gastric Cancer
  • United States
  • World
  • Market Size
  • Merck & Co., Inc.
  • Gastric Cancer - Discontinued Products
  • Gastric Cancer - Overview

Gastric Cancer - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape. Gastric cancer, also called stomach cancer,...

  • Gastric Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative
  • Gastric Cancer - Overview
  • Gastric Cancer - Discontinued Products

Gastric Cancer - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2017, provides an overview of the Gastric Cancer (Oncology) pipeline landscape. Gastric cancer, also called stomach cancer, is a malignant...

  • Gastric Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative
  • Gastric Cancer, Pancreatic Cancer
  • Gastric Cancer, Metastatic Cancer, Metastatic Lung Cancer

Gastric Cancer Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Gastric Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes...

  • Clinical Trial
  • Drug Discovery And Development
  • Gastric Cancer
  • Therapy
  • World
  • Gastric Cancer, Pipeline by Molecular Targets and
  • Gastric Cancer, Molecular Target Family

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs Summary Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with...

  • Cancer
  • Gastric Cancer
  • Pathology
  • United States
  • Deals & Alliance
  • GASTRIC CANCER
  • GASTRIC CANCER

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017 Summary Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling...

  • Gastric Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Product Initiative
  • JUN 19, 2017: THE US FDA GRANTS APATINIB ORPHAN DRUG DESIGNATION FOR TREATMENT OF GASTRIC CANCER
  • MAR 13, 2017: LSK BIOPHARMA ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 APATINIB TRIAL IN GASTRIC CANCER

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H1 2018 Summary Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an...

  • Gastric Cancer
  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer
  • Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer

Summary Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd is a biotechnology company that offers immuno-oncology agents and targeted therapies.The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and...

  • Gastric Cancer
  • Pharmaceutical
  • United States
  • World
  • ASLAN Pharmaceuticals Pte Ltd.
  • Clinical Trial profile. 233 Trial Title
  • Clinical Trial profile. 66 Trial Title

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H2, 2017" provides an overview of Gastroesophageal (GE) Junction Carcinomas clinical trials scenario. This report provides...

  • Clinical Trial
  • Gastric Cancer
  • Lung Cancer
  • World
  • Product Initiative
  • Jul 05, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer
  • 04/20/2017: Five Prime to Present Clinical Data on FPA144 at 2017 ASCO Annual Meeting

Summary Five Prime Therapeutics Inc (Five Prime) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders.The company’s developmental pipeline is based on the discovery platform and library of therapeutic proteins. The company’s...

  • Gastric Cancer
  • Therapy
  • United States
  • Company
  • Five Prime Therapeutics, Inc.
  • DIAGNOSTIC TEST - GASTRIC CANCER
  • DIAGNOSTIC TEST - GASTRIC CANCER - PRODUCT DESCRIPTION

Summary Miraculins Inc. (Miraculins) is a biotechnology company that offers therapeutic products. The company acquires, develops and commercializes risk assessment tests, and non invasive diagnostic tests for the healthcare market. It provides discovery and validation of cancer biomarkers for development of diagnostic tools and...

  • Colorectal Cancer
  • Diabetes
  • Gastric Cancer
  • Pharmacy
  • Miraculins Inc.
  • Products under Development by Companies, H2 2017
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2017 Summary According to the recently published report ’Tyrosine Protein Kinase CSK - Pipeline Review, H2 2017’; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC...

  • Cancer
  • Gastric Cancer
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.